Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7074724
Reference Type
Journal Article
Title
Pioglitazone (Actos, Glustin) A Drug That Transformed Diabetes Therapy
Author(s)
Takada, N; Genda, K; ,
Year
2019
Publisher
SPRINGER-VERLAG SINGAPORE PTE LTD
Location
SINGAPORE
Book Title
DRUG DISCOVERY IN JAPAN: INVESTIGATING THE SOURCES OF INNOVATION
Page Numbers
169-181
DOI
10.1007/978-981-13-8906-1_10
Web of Science Id
WOS:000566291300011
Abstract
Pioglitazone was an early member of a new category of diabetes treatment drugs called insulin sensitizers, pioneered by Takeda Pharmaceutical. It is used for the treatment of Type 2 diabetes, and acts by lowering blood glucose levels. The thiazolidinedione backbone discovered by Takeda Pharmaceutical was widely adopted in industry. Research on pioglitazone began as a result of serendipitous discovery of its lead compound during research on lipid-lowering agents. New animal models made a major contribution to understanding the pathogenesis of diabetes in basic research, but also led the researchers to the discovery of compounds with thiazolidinedione backbone that improve insulin sensitivity. Although ciglitazone, the first compound studied in clinical trials, failed, pioglitazone was discovered and selected as a candidate compound based on its potent activity, and low propensity to induce side effects. Pioglitazone is a breakthrough drug generated by the culmination of basic research, including the development of animal models, careful screening techniques, and excellent synthesis technologies.
Editor(s)
Nagaoka, S;
ISBN
978-981-13-8905-4
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity